Krystal Biotech (KRYS) Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK in Patients with Dystrophic Epidermolysis Bullosa
Go back to Krystal Biotech (KRYS) Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK in Patients with Dystrophic Epidermolysis Bullosa| (NASDAQ: KRYS) | Delayed: 345.42 -2.67 (0.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $348.09 | 52 Week High | $ | |||
| Open | $347.56 | 52 Week Low | $ | |||
| Day High | $349.66 | P/E | N/A | |||
| Day Low | $344.26 | EPS | $ | |||
| Volume | 81,834 | |||||

